Dewi Putu Itta Sandi Lesmana, Pamungkas Kadek Mercu Narapati, Dewi Ni Luh Putu Yunia, Dewi Ni Nyoman Gita Kharisma, Sindhughosa Dwijo Anargha, Mariadi I Ketut
Centre Research for Alimentary and Hepatobiliary System, Bali, Indonesia.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine Udayana University - Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia.
Acta Med Philipp. 2025 Jun 30;59(8):77-86. doi: 10.47895/amp.vi0.10174. eCollection 2025.
Antibiotic prophylaxis is used to prevent bacterial infections and rebleeding in cirrhosis patients with upper gastrointestinal bleeding (UGIB). However, the effects of various antibiotics on patients with UGIB are still being considered. This study aims to evaluate the effect of antibiotic prophylaxis on cirrhosis patients with UGIB.
The studies were searched through databases of PubMed, ScienceDirect, Wiley Online Library, and CENTRAL from 2013 to 2023. We used Revman 5.4 to perform a meta-analysis. I2 statistics measured the heterogeneity test. The odds ratio (OR) and 95% confidence interval (CI) were used to assess the effect of antibiotic prophylaxis.
Twelve studies involving 14,825 cirrhosis patients were included in this study. Based on the meta-analysis, antibiotic prophylaxis significantly lowered the bacterial infection rate (OR: 0.29, 95%CI: 0.10 to 0.84, = 0.02), and the incidence of serious adverse events (SAE) (OR: 0.50, 95%CI: 0.28 to 0.88, = 0.02) in cirrhosis patients with UGIB.
Administration of antibiotics demonstrated a significant reduction in bacterial infection rates and SAEs. Broad-spectrum non-absorbable antibiotics can be used in cirrhosis patients with UGIB. The appropriate use of antibiotics is important to prevent resistance.
抗生素预防用于预防肝硬化合并上消化道出血(UGIB)患者的细菌感染和再出血。然而,各种抗生素对UGIB患者的影响仍在探讨中。本研究旨在评估抗生素预防对肝硬化合并UGIB患者的效果。
通过检索2013年至2023年的PubMed、ScienceDirect、Wiley Online Library和CENTRAL数据库获取相关研究。我们使用Revman 5.4进行荟萃分析。I²统计量用于衡量异质性检验。比值比(OR)和95%置信区间(CI)用于评估抗生素预防的效果。
本研究纳入了12项涉及14825例肝硬化患者的研究。基于荟萃分析,抗生素预防显著降低了肝硬化合并UGIB患者的细菌感染率(OR:0.29,95%CI:0.10至0.84,P = 0.02)以及严重不良事件(SAE)的发生率(OR:0.50,95%CI:0.28至0.88,P = 0.02)。
使用抗生素可显著降低细菌感染率和严重不良事件的发生率。广谱不可吸收抗生素可用于肝硬化合并UGIB的患者。合理使用抗生素对于预防耐药性很重要。